Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07135531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Continuous Glucose Monitoring (CGM) in an Underserved Population

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Mar 2026 to Mar 19, 2026
    • Site details revised
    v6
  2. Start date: Nov 2025 to Mar 2026
    • Primary and study completion dates: Mar 2027 to Jul 2027
    v5
  3. Start date: Sep 2025 to Nov 2025
    • Primary and study completion dates: Dec 2026 to Mar 2027
    v4
  4. Start date: Aug 2025 to Sep 2025v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tulane University
47 trials monitored
See 8 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
The investigators aim is to conduct a randomized clinical trial in an underserved population who are either uninsured or on Medicaid and taking at least one injection of insulin daily. The investigators believe that this study will lead to considerable alleviation of health disparities and provide better care for an underserved population. This will be a pilot study to evaluate the feasibility of such a trial in this population before doing a larger multicenter trial.
Trial Details
NCT Number NCT07135531
Lead Sponsor Tulane University
Collaborators: Abbott
Conditions
(from sponsor)		 Diabetes, Diabetes Mellitus, Diabetes Type 2
Related terms Diabetes Mellitus, Diabetes Mellitus, Type 2
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov